Kathleen Koerner, DO
Surgery · Gonzales, TXNPI 1093936171
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 40.7% of the total. That places this record below the midpoint for surgery clinicians in TX, where the typical reported total is $2,700.
Across 51 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$360
- Baudax Bio Inc.$183
- Novartis$56
- Kerecis Limited$43
- Pacira Pharmaceuticals Incorporated$37
- Convatec Inc.$36
- plus $170 from 8 others
What the payments were for
- Food & beverage$886100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $360 |
| Baudax Bio Inc. | 15 | $183 |
| Novartis | 1 | $56 |
| Kerecis Limited | 4 | $43 |
| Pacira Pharmaceuticals Incorporated | 2 | $37 |
| Convatec Inc. | 2 | $36 |
| Innocoll Pharmaceuticals Limited | 2 | $32 |
| Abbott | 1 | $29 |
| Exact Sciences | 1 | $25 |
| Cumberland Pharmaceuticals, Inc. | 1 | $24 |
| Amgen | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| KCI USA, Inc. | 1 | $15 |
| Reprise Biomedical, Inc. | 2 | $14 |
How this compares
$886 in reported general payments places this provider in the 30th percentile of 1,830 surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clindamycin Hcl | 19 | $152 |
| Cefdinir | 18 | $104 |
| Tramadol Hcl | 29 | $82 |
| Ciprofloxacin Hcl | 12 | $65 |
Paid to pharmacies, not to this prescriber.
Other surgery in Gonzales
- Michael HarkinsTomball$2.7M
- Douglas StoddardAustin$1.4M
- Steven FassAustin$989K
- Vineet ChoudhryAustin$851K
- Andy HawthorneRound Rock$843K
- Nancy MarquezAustin$700K
- Sachin KukrejaDallas$640K
- Alejandro EsquivelAustin$631K
- Erik WilsonBellaire$610K
- Folahan AyoolaDenton$570K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.